Speaker Profile

Ph.D., CEO & Founder, Siolta Therapeutics

Nikole E. Kimes, Ph.D. is CEO and co-founder of Siolta Therapeutics, a clinical-stage biotech company developing targeted microbiome-based therapeutics and diagnostics for the prevention and treatment of a multitude of diseases, starting with atopic diseases. Dr. Kimes leads the executive, clinical and scientific teams, working with a talented team of scientists and clinicians, blending microbiology, immunology, bioinformatics, and clinical operations expertise to leverage microbiome data for the improvement of patient stratification and development of precision microbial therapeutics. An inventor of Siolta's technology, her research in co-founder Dr. Susan Lynch's lab at UCSF provided the foundation from which the translational research program at Siolta Therapeutics has developed. In addition, Dr. Kimes has over a decade of research experience in microbial ecology and host/microbe interactions, previously supported by a National Science Foundation (NSF) Fellowship, a European Commission FP7 cooperative project (MaCuMBA), and a postdoctoral scholar position at UCSF.

Disrupting the Atopic March: Utilizing the Gut Microbiome to Prevent Allergic Disease Development

 Session Abstract – PMWC 2022 Silicon Valley

Track Chair:
Rita Colwell, Johns Hopkins Bloomberg School of Public Health
Manoj Dadlani, CosmosID

Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the Microbiome field and panel discussions on the challenges for faster adoption.

  • Intro and Overview to Microbiome
    - Manoj Dadlani, CosmosID
  • Regulatory Perspective
    - Scott Jackson, NIST
  • Metabolomics in Drug Development
    - Rangaprasad Sarangarajan, Metabolon
  • Pharma Drug Development (PANEL)
    Session Chair: Karim Dabbagh, Second Genome
    - Jennifer Wortman, Seres Therapeutics
    - Paul Garofolo, Locus Biosciences
    - Rangaprasad Sarangarajan, Metabolon
  • AI in Microbiome
    - Agnieszka Piotrowska, Ardigen
  • Direct-To-Consumer Testing/Technologies (PANEL)
    Session Chair: Nathan D. Price, Thorne HealthTech
    - Kiran Krishnan, Microbiome Labs
    - Nicole Scott, Cybele Microbiome
  • The Role of the Human Gut Microbiome on Various Diseases
    - Colleen Cutcliffe, Pendulum Therapeutics
    - Tor Savidge, Baylor College of Medicine
    - Nikole Kimes, Siolta Therapeutics
    - Susan Lynch, UCSF
  • The Gut/Brain Microbiome
    - Mary Conrad, Axial Biotherapeutics
    - Christopher Reyes, Bloom Science
  • Showcase
    - Heloise Breton, DNA Genotek
    - Nathan Price, Thorne HealthTech
    - Manoj Dadlani, CosmosID